We are proud that leading life science investors help to fund our work at Gemini Therapeutics. These investors include Atlas Venture, Lightstone Ventures, OrbiMed Healthcare Fund Management and Wu Capital.
Atlas Venture is a leading biotech venture capital firm. With the goal of doing well by doing good, we have been building breakthrough biotech startups since 1993. We work side by side with exceptional scientists and entrepreneurs to translate high impact science into medicines for patients. Our seed-led venture creation strategy rigorously selects and focuses investment on the most compelling opportunities to build scalable businesses and realize value.
Lightstone Ventures was founded in 2012 by the General Partners and other key members of the life science teams of Advanced Technology Ventures (ATV) and Morgenthaler. The firm was formed to capture the upside of investing in breakthrough life science companies during a time of unique opportunity in the space.
OrbiMed is a leading healthcare investment firm, with over $14 billion in assets under management. OrbiMed invests globally across the healthcare industry, from start-ups to large multinational corporations, utilizing a range of private equity funds, public equity funds, and royalty/credit funds. OrbiMed maintains offices in New York City, San Francisco, Shanghai, Hong Kong, Mumbai and Herzliya. OrbiMed seeks to be a capital provider of choice, providing tailored financing solutions and global team resources and support to help build worldclass healthcare companies.
Wu Capital, founded in 2013, is a leading Chinese evergreen fund with offices in Beijing,Hong Kong and Silicon Valley. Wu Capital partners with top fund managers and talented entrepreneurs worldwide. Wu Capital leverages our extensive industry experience and resources to support the growth of our portfolio companies. We seek to harness the power of innovation through all of our investments. As the only Chinese LP of many top-tier investment funds based in the US and Europe, Wu Capital has developed a robust portfolio comprised of diverse asset classes, hedging against the risk of global market fluctuations. In addition to our fund-of-fund portfolio, Wu Capital has a portfolio direct equity investments across the technology, consumer, education and healthcare sectors.